This is an author correction of the article entitled "Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetic therapy for pancreatic ductal adenocarcinoma". The article was published in Nature Medicine online on January 29, 2026 with DOI: 10.1038/s41591-026-04234-8. It is pancreatic ductal adenocarcinoma (PDAC), one of the most lethal and therapy-resistant human tumors. JQ1 inhibitor of BET family proteins suppresses PDAC development in mice by inhibiting MYC activity and inflammatory signals. The histone deacetylase (HDAC) inhibitor SAHA synergistically potentiates the effect of JQ1, increasing cell death and suppressing advanced PDAC. Using CRISPR-Cas9 in the pancreas of adult mice, derepression of p57 (KIP2 or CDKN1C) after combined BET and HDAC inhibition was shown to be essential for the induction of cell death in PDAC.[1]